Supernus Pharmaceuticals (SUPN) Current Assets (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Current Assets data on file, last reported at $731.6 million in Q1 2026.

• Current Assets for Q1 2026 came in at $731.6 million, up 6.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $731.6 million (up 6.4% YoY), and the FY2025 annual result was $644.2 million, down 6.11% from the prior year.
• Current Assets climbed to $731.6 million in Q1 2026 per SUPN's latest filing, from $644.2 million in the prior quarter.
• Over five years, Current Assets peaked at $883.3 million in Q1 2023 and troughed at $423.5 million in Q2 2023.
• A 5-year average of $629.3 million and a median of $640.0 million in 2024 frame the typical range for Current Assets.
• The sharpest annual moves came in 2023 and 2024: Current Assets surged 55.38% in 2023, then plunged 38.38% in 2024.
• A 5-year view of Current Assets shows it stood at $734.2 million in 2022, then sank by 32.83% to $493.1 million in 2023, then soared by 39.13% to $686.1 million in 2024, then dropped by 6.11% to $644.2 million in 2025, then grew by 13.57% to $731.6 million in 2026.
• Business Quant data shows SUPN's Current Assets at $731.6 million in Q1 2026, $644.2 million in Q4 2025, and $593.9 million in Q3 2025.